Rosetta Genomics (Rosetta Genomics) Other Long Term Assets : $0.01 Mil (As of Jun. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Other Long Term Assets?

Rosetta Genomics's other long-term assets for the quarter that ended in Jun. 2017 was $0.01 Mil.

Rosetta Genomics's quarterly other long-term assets declined from Sep. 2016 ($0.08 Mil) to Dec. 2016 ($0.01 Mil) but then stayed the same from Dec. 2016 ($0.01 Mil) to Jun. 2017 ($0.01 Mil).

Rosetta Genomics's annual other long-term assets increased from Dec. 2014 ($0.00 Mil) to Dec. 2015 ($0.08 Mil) but then declined from Dec. 2015 ($0.08 Mil) to Dec. 2016 ($0.01 Mil).

Rosetta Genomics Other Long Term Assets Historical Data

The historical data trend for Rosetta Genomics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Other Long Term Assets Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Other Long Term Assets

Get a 7-Day Free Trial

0.23

0.01

0.08

0.01

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Other Long Term Assets	Get a 7-Day Free Trial															0.08	0.08	0.08	0.01	0.01

Rosetta Genomics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Executives

Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd.	10 percent owner	C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458

Rosetta Genomics (Rosetta Genomics) Headlines

From GuruFocus

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

By gurufocus • 12-09-2008